Study guide
13.3 Enterocutaneous Fistulas & Severe Malabsorption
Certified Nutrition Support Clinician CNSC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Nutrition Screening, Dietary Evaluation & Energy Requirements
1.1 Nutrition Screening & Validated Risk Tools 1.2 Dietary History & Nutrient Intake Assessment 1.3 Energy Expenditure Estimation & Indirect Calorimetry
2 Chapter 2: Macronutrients, Micronutrients & Fluid Management
2.1 Protein Requirements & Nitrogen Balance 2.2 Fluid Requirements & Electrolyte Homeostasis 2.3 Essential Vitamins & Trace Elements
3 Chapter 3: Anthropometrics, Physical Exam & Malnutrition Consensus
3.1 Anthropometric Assessment & Body Composition 3.2 Nutrition-Focused Physical Examination (NFPE) 3.3 AND/ASPEN & GLIM Malnutrition Criteria
4 Chapter 4: Pediatric & Specialized Nutrition Assessment
4.1 Pediatric & Neonatal Nutrition Assessment 4.2 Biochemical Assessment, Visceral Proteins & Inflammation
5 Chapter 5: Enteral Nutrition Access & Tube Management
5.1 Enteral Access Modalities & Route Selection 5.2 Tube Placement Verification & Stoma Site Care
6 Chapter 6: Enteral Formulation, Regimen Design & Administration
6.1 Enteral Formula Classification & Selection 6.2 Enteral Delivery Methods & Infusion Schedules 6.3 Enteral Fluid Management & Free Water Requirements
7 Chapter 7: Enteral Complications & Medication Administration
7.1 Enteral Gastrointestinal Complications 7.2 Enteral Metabolic, Mechanical & Pulmonary Complications 7.3 Drug-Nutrient Interactions & Enteral Medication Delivery
8 Chapter 8: Parenteral Nutrition Indications, Access & Formulation Design
8.1 Parenteral Nutrition Indications & Venous Access Routes 8.2 Peripheral Parenteral Nutrition (PPN) Parameters 8.3 Central PN Macronutrient Formulation
9 Chapter 9: Parenteral Additives, Compounding & Physical Stability
9.1 Parenteral Electrolytes, Trace Elements & Vitamins 9.2 Calcium-Phosphate Solubility & Precipitation Risks 9.3 Physical Stability, Total Nutrient Admixtures & Filtration
10 Chapter 10: Parenteral Complications, CLABSI & Organ Toxicities
10.1 Central Line-Associated Bloodstream Infections & Mechanical Risks 10.2 Refeeding Syndrome Pathophysiology & Prevention 10.3 Parenteral Nutrition-Associated Liver Disease & Metabolic Bone Disease
11 Chapter 11: Critical Care, Obesity & Pulmonary Nutrition Support
11.1 Critical Illness, Sepsis & Trauma Nutrition 11.2 Nutrition Support in Obesity & Hypocaloric Feeding 11.3 Pulmonary Failure & Mechanical Ventilation 11.4 Nutrition Support Care Plans, Goals & Therapy Reassessment
12 Chapter 12: Organ Failure: Renal, Hepatic & Gastrointestinal Support
12.1 Acute Kidney Injury & Renal Replacement Therapy 12.2 Cirrhosis, Hepatic Encephalopathy & Acute Pancreatitis 12.3 Short Bowel Syndrome & Intestinal Failure
13 Chapter 13: Oncology, Surgical Care & Intestinal Failure
13.1 Oncology Nutrition & Cancer Cachexia 13.2 Perioperative Nutrition & Enhanced Recovery After Surgery (ERAS) 13.3 Enterocutaneous Fistulas & Severe Malabsorption
14 Chapter 14: Process Management, Compounding Safety & Home Nutrition Support
14.1 PN Order Verification, Compounding Safety & USP Standards 14.2 Home Nutrition Support (HNS) & Care Transitions 14.3 Nutrition Support Policies, Product Shortages & Patient Education
15 Chapter 15: Professional Practice, Ethics & Interdisciplinary Care
15.1 Ethical Principles & Withholding/Withdrawing Artificial Nutrition 15.2 The Interdisciplinary Nutrition Support Team 15.3 Quality Improvement, Malnutrition Documentation & Clinical Standards 15.4 Critical Appraisal of Nutrition Research & Evidence
13.3 Enterocutaneous Fistulas & Severe Malabsorption
Key Takeaways Explain This Topic AI
Enterocutaneous fistulas (ECFs) are classified anatomically (proximal vs. distal), by output volume (low <200 mL/d, moderate 200–500 mL/d, high >500 mL/d), and complexity (simple vs. complex/enteroatmospheric).
The SNAP protocol structures fistula management across four chronological phases: Sepsis control & resuscitation, Nutritional support & electrolyte balance, Anatomical delineation, and Planned definitive surgical repair.
Definitive surgical reconstruction must be delayed for at least 3 to 6 months (and 6 to 12 months in open abdomen/frozen abdomen) to allow dense, obliterative vascular adhesions to soften and ensure safe enterolysis.
High-output fistula losses must be replaced milliliter-for-milliliter with balanced crystalloid fluids, alongside mandatory zinc supplementation of 12 to 17 mg of elemental zinc per liter of output.
The FRIEND mnemonic identifies factors preventing spontaneous fistula closure: Foreign body, Radiation, Infection/Inflammation, Epithelialization of tract, Neoplasm, and Distal obstruction.
Last updated: October 2026
13.3 Enterocutaneous Fistulas & Severe Malabsorption
Clinical Core: An enterocutaneous fistula (ECF) is an abnormal epithelialized communication connecting the lumen of the gastrointestinal tract to the cutaneous surface of the abdominal wall. The management of ECF demands strict adherence to the four-phase SNAP protocol : Sepsis control and resuscitation, Nutritional optimization and fluid/electrolyte repletion, Anatomical delineation via contrast imaging, and Planned definitive surgical reconstruction delayed for at least 3 to 6 months 3\text{ to } 6\text{ months} 3 to 6 months . High-output ( > 500 mL/day > 500\text{ mL/day} > 500 mL/day ) and proximal fistulas mandate Parenteral Nutrition (PN), mL-for-mL balanced fluid replacement, and proactive zinc supplementation ( 12 – 17 mg 12\text{--}17\text{ mg} 12 – 17 mg elemental zinc per liter of output). Enteral Nutrition (via fistuloclysis or distal feeding) is viable only when ≥ 75 to 100 cm \ge 75\text{ to } 100\text{ cm} ≥ 75 to 100 cm ( ≥ 4 – 5 feet \ge 4\text{--}5\text{ feet} ≥ 4 – 5 feet ) of healthy, functional distal bowel remains. Clinicians evaluate spontaneous closure probability using the FRIEND mnemonic.
Enterocutaneous Fistula Classification & Pathophysiology
Over 75 % to 85 % 75\%\text{ to } 85\% 75% to 85% of all enterocutaneous fistulas arise as iatrogenic postoperative complications (e.g., inadvertent enterotomies during difficult adhesiolysis, anastomotic disruption, or erosion by synthetic mesh or foreign bodies). The remaining 15 % to 25 % 15\%\text{ to } 25\% 15% to 25% develop spontaneously from Crohn's disease, abdominal radiation, malignant infiltration, or severe diverticular abscesses. +-----------------------------------------------------------------------------------------+
- | ENTEROCUTANEOUS FISTULA CLASSIFICATION |
- +-----------------------------------------------------------------------------------------+
- | Parameter | Category | Clinical Characteristics |
- | --------------------- | ------------------------------- | ----------------------------- |
- | Anatomical Location | Proximal (Stomach, Duodenum, | High volume, enzyme-rich, |
- | | Jejunum) | severe skin digestion, high Na|
- | | Distal (Ileum, Colon) | Low/moderate volume, formed, |
- | | | less caustic, high bacteria |
- | --------------------- | ------------------------------- | ----------------------------- |
- | 24-Hour Output Volume | Low-Output | < 200 mL / 24 hours |
- | | Moderate-Output | 200 to 500 mL / 24 hours |
- | | High-Output | > 500 mL / 24 hours (often |
- | | | reaches 1,000 to 3,000 mL/day)|
- | --------------------- | ------------------------------- | ----------------------------- |
- | Complexity | Simple | Short/direct tract, no abscess,|
- | | | no obstruction, bowel intact |
- | | Complex (Enteroatmospheric, EAF)| Opens directly into open wound|
- | | | bed, frozen abdomen, 0% close |
- +-----------------------------------------------------------------------------------------+
- 1. Anatomical Classification
Proximal Fistulas (Stomach, Duodenum, Jejunum): Effluent contains high concentrations of electrolytes, hydrochloric acid, biliary salts, and pancreatic enzymes (trypsin, chymotrypsin, amylase, lipase). These active proteolytic and lipolytic enzymes induce rapid, severe chemical excoriation and autodigestion of surrounding abdominal skin. Large fluid losses ( 1 to 3 + L/day 1\text{ to } 3+\text{ L/day} 1 to 3 + L/day ) rapidly induce hypovolemia, prerenal azotemia, and profound electrolyte depletion.
Distal Fistulas (Ileum, Colon): Effluent is more formed, lower in volume, contains fewer active digestive enzymes, and poses less risk of caustic skin erosion. However, distal colonic fistulas carry high bacteriological burdens, increasing local wound infection risks.
2. Output Volume Classification
Low-Output: < 200 mL/day < 200\text{ mL/day} < 200 mL/day . High probability of spontaneous closure; electrolyte derangements are uncommon.
Moderate-Output: 200 to 500 mL/day 200\text{ to } 500\text{ mL/day} 200 to 500 mL/day . Intermediate clinical course; requires careful monitoring.
High-Output: > 500 mL/day > 500\text{ mL/day} > 500 mL/day (often exceeding 1000 to 3000 mL/day 1000\text{ to } 3000\text{ mL/day} 1000 to 3000 mL/day in proximal jejunal fistulas). High risk of metabolic collapse, acute kidney injury, micronutrient dumping, and severe malnutrition. Spontaneous closure is rare.
3. Complexity & The Enteroatmospheric Fistula (EAF)
Simple Fistula: Possesses a single, direct cutaneous tract, without an associated intra-abdominal fluid collection, without distal mechanical obstruction, and with bowel wall continuity preserved.
Complex Fistula: Multiple branching tracts, associated active intra-abdominal abscesses, disrupted intestinal continuity, or an enteroatmospheric fistula.
Enteroatmospheric Fistula (EAF): A catastrophic subclass occurring in the setting of an open abdomen (laparostomy). The enteric mucosal defect opens directly into the granulating peritoneal wound bed without overlying soft tissue or skin cover, creating an exposed, "floating" fistula in a "frozen abdomen." Spontaneous closure of an EAF is virtually 0 % 0\% 0% . Management requires specialized isolation appliances (e.g., negative-pressure wound therapy with barrier rings) to prevent enteric effluent from flooding the peritoneal wound, followed by delayed definitive reconstruction.
The "SNAP" Protocol for ECF Management
The clinical management of enterocutaneous fistulas requires a disciplined, chronological approach structured under the SNAP framework: +-----------------------------------------------------------------------------------------+
- | THE "SNAP" MANAGEMENT FRAMEWORK |
- +-----------------------------------------------------------------------------------------+
- | Phase | Primary Objectives | Critical Interventions |
- | --------------------- | ------------------------------- | ----------------------------- |
- | S: Sepsis Control | Eliminate mortality risk, | Image-guided drainage of all |
- | & Resuscitation | restore perfusion and skin | abscesses; targeted IV abx; |
- | (Days 1 to 3) | barrier integrity | isotonic crystalloids; ostomy |
- | --------------------- | ------------------------------- | ----------------------------- |
- | N: Nutritional Support| Achieve positive nitrogen | Protein 1.5-2.5 g/kg/d; PN for|
- | & Metabolic Care | balance; correct zinc and | high-output/proximal; EN via |
- | (Weeks 1 to 6) | electrolyte deficiencies | fistuloclysis if >=75-100cm gut|
- | --------------------- | ------------------------------- | ----------------------------- |
- | A: Anatomy Delineation| Define tract, origin, and | Water-soluble contrast fistulo|
- | (Weeks 2 to 8) | rule out distal obstruction | gram, CT enterography, MRE |
- | --------------------- | ------------------------------- | ----------------------------- |
- | P: Plan Definitive | Safe enterolysis, resection, | Mandatory delay 3 to 6 months |
- | Surgery (Months 3+)| and re-anastomosis | until adhesions soften |
- +-----------------------------------------------------------------------------------------+
- Phase 1: S — Sepsis Control & Resuscitation (Days 1 to 3)
Sepsis as the Primary Killer: Undiagnosed or poorly drained intra-abdominal abscesses account for 60 % to 80 % 60\%\text{ to } 80\% 60% to 80% of all fistula-related deaths . Sepsis drives relentless hypercatabolism, prevents fistula closure, and induces multi-organ failure.
Imaging & Source Control: Immediate contrast-enhanced abdominopelvic CT to locate undrained fluid collections, followed by urgent image-guided percutaneous catheter drainage . Urgent operative exploration during this acute phase is avoided unless percutaneous access is impossible or generalized peritonitis is present.
Resuscitation: Aggressive restoration of circulating blood volume using balanced isotonic crystalloids, targeted broad-spectrum antimicrobial therapy, and correction of prerenal azotemia.
Wound & Skin Protection: Protection of the peristomal skin is vital to prevent full-thickness abdominal wall breakdown. Utilization of custom cut-to-fit ostomy appliances, hydrocolloid wafer barriers, and Negative Pressure Wound Therapy (NPWT) with specialized fistula exclusion techniques ("fistula-VAC").
Phase 2: N — Nutritional Support & Metabolic Care (Weeks 1 to 6)
Hypercatabolism & Nitrogen Deficit: Fistula patients experience severe hypercatabolism; daily protein losses in fistula effluent combined with inflammatory proteolysis generate profound negative nitrogen balances (often − 15 to − 25 g/day -15\text{ to } -25\text{ g/day} − 15 to − 25 g/day of nitrogen , equivalent to losing 100 to 150 g/day 100\text{ to } 150\text{ g/day} 100 to 150 g/day of dry lean tissue protein).
Prescriptions:
Energy: 25 to 35 kcal/kg/day 25\text{ to } 35\text{ kcal/kg/day} 25 to 35 kcal/kg/day (preventing overfeeding);
Protein: 1.5 to 2.5 g/kg/day 1.5\text{ to } 2.5\text{ g/kg/day} 1.5 to 2.5 g/kg/day to achieve positive nitrogen balance and support tissue healing.
Route Selection:
Total Parenteral Nutrition (TPN): The primary, mandatory nutritional modality for all patients with high-output proximal ECFs, complex enteroatmospheric fistulas, or discontinuous gastrointestinal tracts. Enteral feeding in proximal high-output ECFs dramatically stimulates pancreaticobiliary and enteric secretions, exacerbating fluid losses and preventing tract collapse.
Enteral Nutrition (EN): Indicated in low-output or distal ileal/colonic fistulas. In mid-gut or proximal fistulas, enteral nutrition can be delivered via fistuloclysis (intubating the distal efferent limb of the fistula with an enteral feeding tube) or feeding via a distal tube jejunostomy, provided there is at least 75 to 100 cm 75\text{ to } 100\text{ cm} 75 to 100 cm ( ≥ 4 – 5 feet \ge 4\text{--}5\text{ feet} ≥ 4 – 5 feet ) of healthy, non-obstructed, functional distal small bowel between the feeding site and the colon.
Phase 3: A — Anatomy Delineation (Weeks 2 to 8)
Performed only after acute sepsis is completely resolved and the patient is hemodynamically and nutritionally stabilized.
Diagnostic Modalities: Water-soluble contrast fistulogram under fluoroscopy, CT enterography, small bowel follow-through, or magnetic resonance enterography (MRE).
Critical Findings to Document:
Exact anatomical organ of origin (stomach, duodenum, jejunum, ileum, colon);
Length and course of the fistula tract (tracts > 2 cm > 2\text{ cm} > 2 cm favor closure; tracts < 2 cm < 2\text{ cm} < 2 cm resist closure);
- Status of intestinal continuity (lateral defect vs. end disruption);
- Size of the enteric wall defect ( < 1 cm < 1\text{ cm} < 1 cm vs. > 1 cm > 1\text{ cm} > 1 cm );
- Presence or absence of distal mechanical obstruction ;
Presence of foreign bodies, active Crohn's disease, or malignancy.
Phase 4: P — Plan Definitive Surgery (Months 3 to 6+)
The Mandatory Delay Rule: Definitive operative repair must be delayed for at least 3 to 6 months (and frequently 6 to 12 months in patients with an open abdomen, frozen abdomen, or multiple prior laparotomies).
Surgical Biology of the "Hostile Abdomen": Between 1 week and 3 months following initial peritonitis or laparotomy, the peritoneal cavity undergoes an intense inflammatory response, forming dense, vascular, woody, fibrinous adhesions ("obliterative peritonitis"). Operative re-entry during this period inevitably causes catastrophic multiple enterotomies, severe hemorrhage, and recurrent fistulization (recurrence rates > 30 % to 50 % > 30\%\text{ to } 50\% > 30% to 50% ).
Adhesion Maturation: Delaying surgery allows dense vascular adhesions to mature, soften, and organize into pliable, avascular fibrous bands that can be safely divided by meticulous enterolysis.
Operative Goal: Complete resection of the fistula tract and the affected bowel segment, with primary, tension-free end-to-end anastomotic reconstruction through healthy, well-vascularized tissue, followed by durable abdominal wall closure.
Fluid, Electrolyte & Zinc Replacement
High-volume enterocutaneous fistula losses represent an isotonic or slightly hypotonic fluid rich in essential electrolytes and trace elements. +-----------------------------------------------------------------------------------------+
- | TYPICAL ELECTROLYTE COMPOSITION OF GI SECRETIONS |
- +-----------------------------------------------------------------------------------------+
- | Source | Sodium (mEq/L) | Potassium (mEq/L)| Chloride (mEq/L)| Bicarbonate |
- | --------------------- | -------------- | ---------------- | --------------- | ----------- |
- | Gastric | 40 - 100 | 5 - 15 | 100 - 140 | 0 |
- | Biliary / Pancreatic | 130 - 150 | 5 - 10 | 40 - 80 | 30 - 90 |
- | Small Bowel (Jejunal) | 100 - 140 | 5 - 15 | 90 - 120 | 20 - 40 |
- | Small Bowel (Ileal) | 80 - 120 | 5 - 15 | 60 - 90 | 20 - 40 |
- +-----------------------------------------------------------------------------------------+
- 1. Replacement Protocol
Milliliter-for-Milliliter Replacement: All measured fistula losses must be replaced mL-for-mL ( 1 : 1 1:1 1 : 1 ) every 4 to 8 hours using an appropriate intravenous crystalloid solution (e.g., Lactated Ringer's, Plasma-Lyte, or 0.45 % NaCl 0.45\%\text{ NaCl} 0.45% NaCl with added sodium bicarbonate and potassium chloride) tailored to the measured electrolyte content of the drainage.
Separation from Maintenance: Fistula replacement fluids must be administered as an independent infusion, separate from baseline maintenance IVF and Parenteral Nutrition.
Acid-Base Management: High gastric losses produce hypokalemic, hypochloremic metabolic alkalosis (requiring 0.9 % NaCl 0.9\%\text{ NaCl} 0.9% NaCl and K C l KCl K Cl ). High small bowel, biliary, or pancreatic losses waste vast amounts of bicarbonate, producing normal-anion-gap hyperchloremic metabolic acidosis (requiring replacement with sodium bicarbonate or balanced crystalloids with acetate/lactate buffers).
2. Zinc Homeostasis & Supplementation
Upper gastrointestinal secretions, bile, and pancreatic fluid are exceptionally rich in zinc. High-output fistula effluent drains 12 to 17 mg 12\text{ to } 17\text{ mg} 12 to 17 mg of elemental zinc per liter of output .
Clinical Deficiency: Failure to replace zinc results in rapid, severe clinical deficiency manifested by an erythematous, scaling, vesicular periorificial and acral dermatitis (resembling acrodermatitis enteropathica), complete failure of wound healing, impaired epithelialization, intestinal mucosal blunting, diarrhea, alopecia, and cellular immune paralysis.
Dosing Rule: For every liter of high-volume intestinal loss, clinicians must supplement 12 to 17 mg 12\text{ to } 17\text{ mg} 12 to 17 mg of elemental zinc daily (added to TPN or infused intravenously as trace elements) above standard maintenance requirements ( 2.5 to 5.0 mg/day 2.5\text{ to } 5.0\text{ mg/day} 2.5 to 5.0 mg/day ).
Pharmacological Adjuncts in ECF Management +-----------------------------------------------------------------------------------------+
- | PHARMACOTHERAPY IN ENTEROCUTANEOUS FISTULA |
- +-----------------------------------------------------------------------------------------+
- | Drug Class | Mechanism | Clinical Utility & Limits |
- | --------------------- | ------------------------------- | ----------------------------- |
- | Proton Pump Inhibitors| Blocks gastric H+/K+ ATPase, | Decreases proximal output by |
- | (e.g., Pantoprazole) | suppressing acid secretion | 1 to 2 L/day; protects skin |
- | --------------------- | ------------------------------- | ----------------------------- |
- | Somatostatin Analogues| Inhibits GI endocrine/exocrine | Reduces output volume by 50%; |
- | (e.g., Octreotide) | secretions; slows transit | DOES NOT INCREASE CLOSURE RATE|
- | --------------------- | ------------------------------- | ----------------------------- |
- | Antimotility Agents | Mu-opioid receptor agonist; | Prolongs transit; useful in |
- | (e.g., Loperamide) | blunts peristaltic contractions | distal/low-output fistulas |
- +-----------------------------------------------------------------------------------------+
- 1. Antisecretory Agents
Proton Pump Inhibitors (PPIs, e.g., IV Pantoprazole 40 – 80 mg/day 40\text{--}80\text{ mg/day} 40 – 80 mg/day ): Profoundly suppresses gastric acid production, reducing fluid volume traversing gastroduodenal and proximal jejunal fistulas by 1 to 2 L/day 1\text{ to } 2\text{ L/day} 1 to 2 L/day . This simplifies fluid balance, protects the abdominal wall from acid digestion, and reduces bicarbonate consumption.
Somatostatin Analogues (Octreotide 100 – 200 mcg 100\text{--}200\text{ mcg} 100 – 200 mcg subcutaneous TID or continuous IV infusion): Inhibits gastrin, secretin, cholecystokinin, motilin, and pancreaticobiliary secretions, cutting fistula output by up to 50 % 50\% 50% within 24 to 48 hours 24\text{ to } 48\text{ hours} 24 to 48 hours .
Critical Evidence Caveat: Multiple randomized controlled trials and meta-analyses establish that while octreotide reliably decreases fistula volume (facilitating fluid management and pouching), it does NOT increase the ultimate rate of spontaneous fistula closure , nor does it shorten time to definitive surgery. If fistula volume does not decrease after 48 to 72 hours 48\text{ to } 72\text{ hours} 48 to 72 hours , octreotide should be discontinued.
2. Antimotility Agents
Loperamide ( 2 to 4 mg 2\text{ to } 4\text{ mg} 2 to 4 mg dosed 30 minutes before meals and at bedtime, titrated up to 16 mg/day 16\text{ mg/day} 16 mg/day ): Acts on intestinal circular and longitudinal smooth muscle μ \mu μ -opioid receptors to slow intestinal transit. Useful in low-output or distal fistulas receiving enteral or oral intake to maximize mucosal contact time and water absorption.
Spontaneous Closure Predictors: The FRIEND Mnemonic
Spontaneous closure occurs in approximately 20 % to 40 % 20\%\text{ to } 40\% 20% to 40% of enterocutaneous fistulas under conservative medical and nutritional management. Clinicians utilize the classic FRIEND mnemonic to identify factors that prevent spontaneous closure: +-----------------------------------------------------------------------------------------+
- | FACTORS PREVENTING CLOSURE: THE "FRIEND" MNEMONIC |
- +-----------------------------------------------------------------------------------------+
- | Letter | Factor | Pathophysiological Mechanism |
- | ------ | ----------------------- | ---------------------------------------------------- |
- | F | Foreign body | Synthetic mesh, drain, or suture erodes tract lumen |
- | R | Radiation | Endarteritis obliterans, chronic ischemia & fibrosis |
- | I | Infection / Inflammation| Undrained abscess, active sepsis, or Crohn's disease |
- | E | Epithelialization | Tract < 2 cm; mucocutaneous continuity forms bridge |
- | N | Neoplasm | Tumor cells invade tract, preventing tissue adhesion |
- | D | Distal obstruction | Intraluminal hydrostatic backpressure forces leakage |
- +-----------------------------------------------------------------------------------------+
- Factors Favoring Spontaneous Closure
- Low Output: < 200 mL/day < 200\text{ mL/day} < 200 mL/day ;
- Long Tract: Length > 2 cm > 2\text{ cm} > 2 cm (provides resistance to flow and permits granulation);
- Small Bowel Defect: Enteric wall defect < 1 cm < 1\text{ cm} < 1 cm ;
- Anatomical Origin: Lateral duodenal, jejunal, or distal ileal fistulas with bowel continuity preserved;
Absence of FRIEND Criteria: No foreign body, radiation, sepsis, epithelialization, malignancy, or distal obstruction;
Nutritional Repletion: Normalizing visceral proteins (positive nitrogen balance).
Natural History & Timeline of Closure
Spontaneous closure, when achievable, occurs almost universally within 4 to 6 weeks of achieving sepsis control and optimal nutritional repletion. If a fistula continues to drain beyond 6 to 8 weeks under optimal conservative management, spontaneous closure is virtually impossible ( < 5 % < 5\% < 5% probability). At that point, further conservative delays are futile, and management transitions to outpatient home nutritional rehabilitation while awaiting delayed definitive surgical reconstruction at 3 to 6 months.